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We report multiple synchronous clear-cell chondrosarcomas in a 43-year-old patient. The patient had a lesion in the
right proximal humerus and in the left femoral condyle. Bone scintigraphy revealed increased uptake in both foci.
Pathological analysis confirmed the diagnosis in both locations. In the proximal humerus, wide resection of the
tumour was performed with allograft reconstruction of the joint with osteosynthesis. The femoral condyle was
treated with curettage, phenolization, and cementation. Over a follow-up of 10 years no recurrence or metastasis
was observed.
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Clear-cell chondrosarcoma (CCC) was first described by
Unni et al. [1] as a variant of conventional chondrosar-
coma and is considered as a low-grade malignant bone
tumor. There is a male prevalence of 2:1 and the tumor
most commonly occurs in the 3rd and 5th decade of
life [1,2].
The tumor is most frequently found in the epiphysis
of the long bones (humerus and proximal femur). Most
authors agree that the management of choice is wide re-
section. The estimated survival rate at 5 years is 92%
[2,3]. Metastases to the lungs or other bones have been
reported [1]. In 2006 Corradi et al. [4] presented four
patients with aggressive CCC (with early metastasis or
multiple tumor location). Case 4 of Corradi’s series is
the patient we are presenting here. We currently doubt
the aggressive presentation as the patient has not pre-
sented with any local tumor recurrence or metastasis
during 10 years of follow-up.
Here we report a case of synchronous CCC with a fa-
vorable outcome at 10 years.
Case report
A 43-year-old male patient was seen with a one-year his-
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unless otherwise stated.motion of the joint. Radiographs revealed a lytic lesion
in the proximal epiphyseal humerus, with calcifica-
tions, and cortical thinning and expansion of the bone
(Figure 1a). Computed tomography (CT) scan of the
shoulder revealed a 5-cm-long intracompartimental
lesion with cortical thinning and popcorn-like calcifi-
cations (Figure 1b). Magnetic resonance imaging (MRI) of
the shoulder showed an hypointense on T1- and hyperin-
tense on T2-weighted images lesion occupying almost the
entire humeral epiphysis, with a preserved cortex and no
soft-tissue involvement (Figure 1c).
Bone scintigraphy showed increased uptake in two le-
sions: in the proximal humerus- already known - and in
the contralateral distal femur - an asymptomatic lesion
(Figure 2).
Radiographs of the knee confirmed a lytic lesion in the
medial condyle with a sclerotic margin. The lesion was
clinically asymptomatic and the patient had full range of
motion in the joint (Figure 3a). CT scan of the knee con-
firmed a well-circumscribed lytic lesion with a sclerotic
rim, cortical thinning without disruption of the bone
(Figure 3b) . MRI of the knee displayed a round homo-
geneous well limited hypodense on T1-weighted sequence
lesion (Figure 3c).
CT scan of the thorax was normal and alkaline phos-
phatase within normal limits.
Needle biopsies were performed and the diagnosis of
CCC was confirmed in both sites (Figures 1d and 3d).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Humeral tumor. a: Radiograph of the humerus reveals a lytic proximal lesion with cortical thinning and intralesional calcifications.
b: CT scan of the shoulder showing intralesional popcorn-like calcifications. c: MRI T1 images lesion occupying almost the entire humeral epiphysis,
with a preserved cortex and no soft-tissue involvement. d: Hematoxylin and eosin staining of clear-cell chondrosarcoma in the humerus consisting
of plump cells with well-defined cytoplasmic borders, clear-to-pale eosinophilic cytoplasm and round nuclei. Mitotic figures are scanty and amounts
of woven bone are present (x100 magnification). 1e: Joint allograft, without signs of recurrence.
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formed followed by allograft reconstruction of the joint
with osteosynthesis. The femoral condyle lesion was
treated with curettage, phenolization, and cementation, in
the same time (Figures 1e and 3e). Clinical and imaging
follow-up (CT scan of the thorax and radiographs of the
knee and shoulder) were performed every six months for
three years and yearly thereafter. Over a postoperative
follow-up of 10 years, no recurrence or metastasis was
found.
Discussion
CCC is a rare low grade variant accounting for 2% of
all chondrosarcomas [1,5,6]. The most frequent symp-
tom is long-term unspecific local pain. Bjorgsson et al.
[5] reported that in their series of 47 patients 55% had
had a history of symptoms for more than one year,which may be attributed to the slow growth of the
tumour [1,6,7]. Although Collins et al. [8] described
that tumor located in the proximal humerus was radio-
logically more aggressive, we have not observed any
local recurrence after a follow-up of 10 years. Histo-
logical findings showed proliferation of polyhedric
clear cells with distinct cytoplasmic borders and cen-
tral nuclei, giant multinucleated cells, and scattered
areas of conventional low-grade chondrosarcoma as
well as calcifications within the tumor [8]. These au-
thors suggest that there is a subgroup of CCC with a
worse outcome, not predictable by conventional histo-
pathalogical analysis. In these tumours, less expression
of certain cell-membrane proteins may contribute to
increased clinical aggressiveness. The management of
choice is wide tumor resection [1,2,4-6,9,10]. Accord-
ing to Bjorgsson et al. [6] with this treatment modality
Figure 2 Whole-body bone scan with increased uptake in
two foci.
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mendation, intralesional resection was chosen in our
lesion of the femoral condyle as the lesion was consid-
ered non active and was clinically asymptomatic (an inci-
dental finding on whole-body bone scan). Local recurrence
after inadequate resection was found to be 83% and
86% [1 and 6, respectively]. In the literature local recur-
rence at 19 years [11] and metastatic disease at 23 years
[2] postoperatively have been described. Although,
Donati et al. [5] conclude in their report of 18 cases that al-
kaline phosphatase may be used in the follow-up as a
marker of tumor recurrence and metastasis, in our patient
alkaline phosphatase levels were within normal limits
both before surgery and during the follow-up period.
The condylar lesion had clinical and imaging features
that were similar to epiphyseal chondroblastoma; but
the patient was too old, and there was no inflammatory
reaction on MR,as usually seen in chondroblastoma. Some
authors suggest that CCC may be a malignant chondro-
blastoma [11,12]. Achim [11] concludes that epiphyseal
chondroblastomas occur in younger patients, have a
smaller size (from 1 to 4 cm), and are more confined to
the epiphysis than CCC.
We found no multiple synchronous or not CCC re-
ported in the literature [4]. Recurrences and bone me-
tastasis during follow-up have been described. Our case
has multiple location at the time of diagnosis. Could the
condyle lesion be metastatic? Is the humerus the pri-
mary location? Or the opposite, which is much more
probable, as the humerus lesion is active and the femoral
not? On histology, the diagnosis of CCC was definitively
confirmed, however, differentiation between a primary
and a metastatic lesion is not possible. Immunohisto-
chemically we can make the differential diagnosis, with
other pathologies containing clear cells (kidney or lung
adenocarcinoma metastastasis), but not between a pri-
mary tumor and a metastasis . CCC is positive for S-100
protein (CD 10 -), however, in metastasis, cytokeratins
and CD 10 are positive. Karyotyping was not done, as
fresh tissue was not planed at the time of the treatment.
It could have helped.
Unni et al. [1] reported two patients with multiple
bone involvement considered to be metastases and not
multiple primary tumors, as visceral metastases were
also found.
Unfortunately, in our case previous radiographs of the
knee were not available. As in this location the lesion
was small, asymptomatic, and was an incidental finding
on the bone scintigraphy while physical examination was
normal and the imaging findings indicated a non aggres-
sive lesion, it was considered to be an inactive lesion.
The fact that the patient had no other metastasis in the
follow-up is also in favor of two primary lesions, even if
formal proof cannot be established. Due to the slow
Figure 3 Imaging of the knee. a: radiograph: well limited lytic condylar image with a sclerotic rima. b: Axial CT scan of the knee showing a lytic
lesion with calcifications and without cortical disruption. c: MRI T2-weighted image shows a homogeneously hypointense and well delineated
lesion. There is no peri lesional edema. d: Femur clear cell chondrosarcoma on hematoxylin and eosin staining shows morphologically an indistinct
lobularity and fine fibrovascular septa separate sheets of clear cells associated to delicate trabeculae of osteoid and rare multinucleated giant cells
(x100 of magnification). e: Radiograph of the knee after curettage, phenolization, and cementation.
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CCC, as local recurrence more than 20 years post-
operatively has been described.Consent
Written informed consent was obtained from the patient
(it is the way accepted by our ethicalcommittee for old
patients). Approved by the ethical committee of the Rizzoli
Institute.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MM operated and followed the patient, proposed the subject. SF wrote the
article. AR provided and checked the histology. JM checked the article. DV
provided the images, and supervised the article. All authors read and
approved the final manuscript.
Author details
1Department of Surgery, The Rizzoli Institute, Via di Barbiano 1/1o, 40136
Bologna, Italia. 2Department of Pathology, The Rizzoli Institute, Via di
Manfrini et al. Clinical Sarcoma Research 2014, 4:12 Page 5 of 5
http://www.clinicalsarcomaresearch.com/content/4/1/12Barbiano 1/1o, 40136 Bologna, Italia. 3Department of Research, The Rizzoli
Institute, Via di Barbiano 1/1o, 40136 Bologna, Italia.
Received: 11 July 2014 Accepted: 8 September 2014
Published: 16 September 2014
References
1. Unni KK, Dahlin DC, Beabout JW, Sim FH: Chondrosarcoma: clear-cell variant.
A report of sixteen cases. J Bone Joint Surg Am 1976, 58:676–683.
2. Bagley L, Kneeland JB, Dalinka MK, Bullough P, Brooks J: Unusual behavior
of clear cell chondrosarcoma. Skeletal Radiol 1993, 22:279–282.
3. Yamaguchi H, Isu K, Ubayama Y, Yamawaki S, Gotoh M, Miyagawa A,
Minami A, Matsuno T, Sasaki T, Nojima T: Clear cell chondrosarcoma. A
report of two cases and review of literature. Acta Pathol Jpn 1986,
36:1577–1585.
4. Corradi D, Bacchini P, Campanini N, Bertoni F: Aggressive clear cell
chondrosarcoma: do distinctive charasteristics exist?: a report of 4 cases.
Arch Pathol Lab Med 2006, 130:1673–1679.
5. Donati D, Yin JQ, Colangeli M, Colangeli S, Bella CD, Bacchini P, Bertoni F:
Clear cell chondrosarcoma of bone: long time follow-up of 18 cases.
Arch Orthop Trauma Surg 2008, 128:137–142.
6. Bjornsson J, Unni KK, Dahlin DC, Beabout JW, Sim FH: Clear cell
chondrosarcoma of bone. Observations in 47 cases. Am J Surg Pathol.
1984, 8:223–30.
7. Ayoub K, Grimer R, Mangham D, Carter S: Tillman D&R Clear cell
chondrosarcoma of bone. Sarcoma 1999, 3:115–9.
8. Collins MS, Koyama T, Swee RG: Inwaeds CY Clear cell chondrosarcoma:
radiographic, computed tomographic, and magnetic resonance findings
in 34 patients with pathologic correlation. Skeletal Radiol. 2003, 32:687–694.
9. Cannon CP, Nelson SD, Seeger LL, Eckardt JJ: Clear cell chondrosarcoma
mimicking chondroblastoma in a skeletally immature patient. Skeletal
Radiol 2002, 31:369–372.
10. Le Charpentier Y, Forest M, Postel M, Tomeno B, Abelanet R: Clear-cell
chondrosarcoma: a report of five cases including ultrastructural study.
Cancer 1979, 44:622–629.
11. Kaim AH, Hugli R, Bonel HM, Judnt G: Chondroblastoma and clear cell
chondrosarcoma: radiological and MRI charasteristics with
histophatological correlation. Skeletal Radiol 2002, 31:88–95.
12. Schajowitz F: Tumors and tumor-like lesions of bone and joints. New York:
Springer-Verlag; 1981:195–198.
doi:10.1186/2045-3329-4-12
Cite this article as: Manfrini et al.: Multiple or metastatic clear cell
chondrosarcoma: a case report. Clinical Sarcoma Research 2014 4:12.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
